ArticleHuman brain mapping2025
MRI Distance Measures as a Predictor of Subsequent Clinical Status During the Preclinical Phase of Alzheimer's Disease and Related Disorders.
Article in Human brain mapping, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Brain atrophy over time, as measured by magnetic resonance imaging (MRI), has been shown to predict subsequent cognitive impairment among individuals who were cognitively normal when first evaluated, indicating that subtle brain atrophy associated with Alzheimer's disease (AD) may begin years before clinical symptoms appear. Traditionally, atrophy has been quantified by differences in brain volume or thickness over a specified timeframe. Research indicates that the rate of atrophy varies across different brain regions, which themselves exhibit complex spatial and hierarchical organizations. These characteristics collectively emphasize the need for diverse summary measures that can effectively capture the multidimensional nature of degeneration. In this study, we explore the use of distance measurements to quantify brain volumetric changes using processed MRI data from the Preclinical Alzheimer's Disease Consortium (PAC). We conducted a series of analyses to predict future diagnostic status by modeling MRI trajectories for participants who were cognitively normal at baseline and either remained cognitively normal or progressed to mild cognitive impairment (MCI) over time, with adjustments for age, sex, education, and APOE genotype. We consider multiple distance measures and brain regions through a two-step approach. First, we build base models by fitting individual mixed-effect models for each distance metric and brain region pairing, using follow-up diagnosis (normal vs. MCI) as the outcome and volumetric changes from the baseline, as summarized by a given distance measure, as predictors. The second step aggregates these individual region-distance base models to derive an overall estimate of diagnostic status. Our analyses showed that the distance measures approach consistently outperformed the traditional direct volumetric approach in terms of predictive accuracy, both in individual base models and the aggregated models. This work highlights the potential advantage of using distance measures over the traditional direct volumetric approach to capture the multidimensional aspects of atrophy in the development of AD and related disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.